Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 1237 results for pain

  1. What is the clinical and cost effectiveness of lidocaine patches for localised peripheral pain?

    peripheral pain? Any explanatory notes(if applicable) Source guidance details Comes from guidance Neuropathic pain in...

  2. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  3. Managing breakthrough pain:- What is the acceptability, safety, and effectiveness of different types of opioid analgesia for breakthrough pain in children and young people with life-limiting conditions who are having end of life care in the community?

    Managing breakthrough pain:- What is the acceptability, safety, and effectiveness of different types of opioid analgesia for...

  4. Naldemedine for treating opioid-induced constipation (TA651)

    Evidence-based recommendations on naldemedine (Rizmoic) for treating opioid-induced constipation in adults who have had laxative treatment.

  5. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

  6. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

  7. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

  8. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  9. Pain management: chronic pancreatitis:- Is the long-term use of opioids more clinically effective and cost effective than non-opioid analgesia (including non-pharmacological analgesia) in people with chronic pain due to chronic pancreatitis?

    Recommendation ID NG104/3 Question Pain management: chronic pancreatitis:- Is the long-term use of opioids more clinically effective and

  10. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

  11. Eliglustat for treating type 1 Gaucher disease (HST5)

    Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.

  12. Multimorbidity: clinical assessment and management (NG56)

    This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

  13. Food allergy in under 19s: assessment and diagnosis (CG116)

    This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.

  14. Human and animal bites: antimicrobial prescribing (NG184)

    This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.